{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:04:45Z","timestamp":1787025885729,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,1,19]]},"abstract":"<jats:p>Background: Although previous phase II and III clinical trials conducted in Japan showed that zonisamide improved parkinsonism in patients with dementia with Lewy bodies (DLB), some differences in efficacy outcomes were observed between the trials. Objective: We aimed to further examine the efficacy and safety of zonisamide in DLB patients with parkinsonism in a post hoc analysis of pooled data from the previous phase II and III trials. Methods: Both trials featured a 4-week run-in period followed by a 12-week treatment period with a double-blind, placebo-controlled, parallel-group, randomized, multicenter trial design. In our pooled analysis, the primary outcome was the change in Unified Parkinson\u2019s Disease Rating Scale (UPDRS) part III total score. Other outcomes included the changes in Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory-10 (NPI-10) scores, and the incidence of adverse events. Results: Zonisamide significantly decreased the UPDRS part III total and individual motor symptom scores but did not affect the MMSE or NPI-10 scores at week 12. There was no difference in the incidence of adverse events between the zonisamide and placebo groups except for decreased appetite, which had an increased frequency in the zonisamide 50\u200amg group compared with placebo. Conclusion: Our findings indicate that zonisamide improved parkinsonism with DLB without deterioration of cognitive function and or worsening behavioral and psychological symptoms of dementia.<\/jats:p>","DOI":"10.3233\/jad-200893","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T12:42:58Z","timestamp":1608036178000},"page":"627-637","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials"],"prefix":"10.1177","volume":"79","author":[{"given":"Kazuko","family":"Hasegawa","sequence":"first","affiliation":[{"name":"Neurology, National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kochi","sequence":"additional","affiliation":[{"name":"Data Science, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Konishi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Toya","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinari","family":"Odawara","sequence":"additional","affiliation":[{"name":"Health Management Center, Yokohama City University, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200893_ref1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","article-title":"Dementia with Lewy bodies","volume":"3","author":"McKeith","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-200893_ref2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-200893_ref3","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JAD-200893_ref4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/mds.26327","article-title":"Loss of dopamine transporter binding and clinical symptoms in dementia with Lewy bodies","volume":"31","author":"Siepel","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-200893_ref5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1212\/WNL.48.2.376","article-title":"Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson\u2019s disease","volume":"48","author":"Louis","year":"1997","journal-title":"Neurology"},{"key":"10.3233\/JAD-200893_ref6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/mds.10455","article-title":"Extrapyramidal features in Parkinson\u2019s disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study","volume":"18","author":"Burn","year":"2003","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-200893_ref7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.JGP.0000216177.08010.f4","article-title":"More severe functional impairment in dementia with Lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction","volume":"14","author":"McKeith","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.3233\/JAD-200893_ref8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000017108","article-title":"The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"10","author":"Ballard","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-200893_ref9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1017\/S1041610209008631","article-title":"Characteristics of eating and swallowing problems in patients who have dementia with Lewy bodies","volume":"21","author":"Shinagawa","year":"2009","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-200893_ref10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1212\/WNL.61.7.944","article-title":"The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies","volume":"61","author":"Murman","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JAD-200893_ref11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/WAD.0b013e318065c4a9","article-title":"Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease","volume":"21","author":"Bostr\u00f6m","year":"2007","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-200893_ref12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/geront\/gnq055","article-title":"Stress and burden among caregivers of patients with Lewy body dementia","volume":"51","author":"Leggett","year":"2010","journal-title":"Gerontologist"},{"key":"10.3233\/JAD-200893_ref13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/gps.4433","article-title":"Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"31","author":"Svendsboe","year":"2016","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-200893_ref14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","article-title":"Pharmacological management of Lewy body dementia: A systematic review and meta-analysis","volume":"172","author":"Stinton","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.3233\/JAD-200893_ref15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/jnnp.2004.052332","article-title":"The role of levodopa in the management of dementia with Lewy bodies","volume":"76","author":"Molloy","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-200893_ref16","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/mds.22322","article-title":"Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies","volume":"23","author":"Goldman","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-200893_ref17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"key":"10.3233\/JAD-200893_ref18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ncn3.12026","article-title":"Randomized placebo-controlled trial of zonisamide in patients with Parkinson\u2019s disease","volume":"4","author":"Murata","year":"2016","journal-title":"Neurol Clin Neurosci"},{"key":"10.3233\/JAD-200893_ref19","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.26286","article-title":"Zonisamide improves wearing-off in Parkinson\u2019s disease: A randomized, double-blind study","volume":"30","author":"Murata","year":"2015","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-200893_ref20","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-200893_ref21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","article-title":"Effects of zonisamide on dopaminergic system","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res"},{"key":"10.3233\/JAD-200893_ref22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neures.2017.05.008","article-title":"Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity","volume":"124","author":"Uemura","year":"2017","journal-title":"Neurosci Res"},{"key":"10.3233\/JAD-200893_ref23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/1381612043453180","article-title":"Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson\u2019s disease","volume":"10","author":"Murata","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.3233\/JAD-200893_ref24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.pbb.2010.11.014","article-title":"Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats","volume":"97","author":"Miwa","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.3233\/JAD-200893_ref25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2018.05.013","article-title":"Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study","volume":"391","author":"Ikeda","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-200893_ref26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ncn3.12103","article-title":"Efficacy of a novel drug, zonisamide, in the modulation of oxidative stress in Parkinson\u2019s disease","volume":"5","author":"Hirayama","year":"2017","journal-title":"Neurol Clin Neurosci"},{"key":"10.3233\/JAD-200893_ref27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12149-016-1099-2","article-title":"Extrastriatal spreading of microglial activation in Parkinson\u2019s disease: A positron emission tomography study","volume":"30","author":"Terada","year":"2016","journal-title":"Ann Nucl Med"},{"key":"10.3233\/JAD-200893_ref28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1440-1819.2010.02075.x","article-title":"Administration of zonisamide in three cases of dementia with Lewy bodies","volume":"64","author":"Odawara","year":"2010","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.3233\/JAD-200893_ref29","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","article-title":"Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized, double-blind phase 2 study","volume":"90","author":"Murata","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JAD-200893_ref30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.parkreldis.2019.12.005","article-title":"Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial","volume":"76","author":"Murata","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JAD-200893_ref31","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.3233\/JAD-200893_ref32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/archneurol.2009.295","article-title":"The clinically important difference on the unified Parkinson\u2019s disease rating scale","volume":"67","author":"Shulman","year":"2010","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-200893_ref33","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.3233\/JAD-200893_ref34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-200893_ref35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000375363","article-title":"Clinical and neuropsychological differences between mild Parkinson\u2019s disease dementia and dementia with Lewy bodies","volume":"5","author":"Petrova","year":"2015","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"10.3233\/JAD-200893_ref36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000447586","article-title":"Pretreatment cognitive profile likely to benefit from donepezil treatment in dementia with Lewy bodies: Pooled analyses of two randomized controlled trials","volume":"42","author":"Mori","year":"2016","journal-title":"Dement Geriatr Cogn Dis"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:36Z","timestamp":1777370676000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":36,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-200893","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]}}}